S2 Episode 3: Can We Prevent Myelofibrosis? The New Interferon Era

Join Drs Tania Jain and Brandi Reeves as they discuss primary myelofibrosis and post-ET (essential thrombocythemia) and post-PV (polycythemia vera) myelofibrosis.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002055. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Primary MF https://emedicine.medscape.com/article/197954-overview

Pegylated Interferon: The Who, Why, and How https://pubmed.ncbi.nlm.nih.gov/39644027/

Genetic Background of PV https://pubmed.ncbi.nlm.nih.gov/35456443/

Ropeginterferon Alfa-2b vs Standard Therapy for Polycythaemia Vera (PROUD-PV and CONTINUATION-PV): A Randomised, Non-inferiority, Phase 3 Trial and Its Extension Study https://pubmed.ncbi.nlm.nih.gov/32014125/

Insights Into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms https://pubmed.ncbi.nlm.nih.gov/35162937/

Nationwide Prospective Survey of Secondary MF in Japan: Superiority of DIPSS-Plus to MYSEC-PM as a Survival Risk Model https://pubmed.ncbi.nlm.nih.gov/37463903/

Prognostication in Myeloproliferative Neoplasms, Including Mutational Abnormalities https://pubmed.ncbi.nlm.nih.gov/36922447/

ASXL1 Mutations Are Prognostically Significant in PMF, but Not MF Following Essential Thrombocythemia or PV https://pubmed.ncbi.nlm.nih.gov/35020812/

Genomic Analysis of Primary and Secondary MF Redefines the Prognostic Impact of ASXL1 Mutations: A FIM Study https://pubmed.ncbi.nlm.nih.gov/33666653/

Thromboembolic Events in PV https://pubmed.ncbi.nlm.nih.gov/30848334/

Optimal Treatment for Patients With Cavernous Transformation of the Portal Vein https://pubmed.ncbi.nlm.nih.gov/35402447/

Cytoreduction for ET and PV: Who, What, When, and How? https://pubmed.ncbi.nlm.nih.gov/38066871/